Zacks Investment Research·Sep 10, 2026
Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock?
Tango Therapeutics' investment case hinges on its synthetic lethality pipeline, but near-term fundamentals are dominated by milestone-driven revenue volatility and escalating operating costs. The $700M equity raise in 2026Q2 bolsters liquidity to $345.6M, yet ...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 10, 2026 | -$0.37-16.6% vs -$0.32 | — vs $2M |
Q2 2026 May 13, 2026 | -$0.32-2.0% vs -$0.31 | — vs $578,091 |
Q2 2026 Mar 5, 2026 | -$0.29+6.5% vs -$0.31 | — vs $500,400 |
Q4 2025 Nov 4, 2025 | $0.13+1200.0% vs $0.01 | $54M+9578.2% vs $556,000 |
Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock?
BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 146,500 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.
BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT.
Algert Global LLC boosted its holdings in shares of Tango Therapeutics, Inc. (NASDAQ: TNGX) by 86.5% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 271,570 shares of the company's stock after purchasing an additional 125,930 shares during the
Benchmark TNGX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Tango Therapeutics, Inc. (TNGX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $25.53 | $4.16B | -29.34 | 48.29% | -162.85% | -37.23% | — | |
| $192.86 | $41B | -32.41 | — | — | -96.44% | — | |
| $122.06 | $10.04B | -33.08 | -16.72% | -285.41% | -21.5% | — | |
| $300.65 | $8.38B | -22.30 | -100% | — | -34.15% | — | |
| $16.67 | $2.14B | 8.05 | 20.38% | 100.84% | 59% | — | |
| $1.51 | $80.53M | -1.02 | — | — | -78.11% | — |
Tango Therapeutics, Inc. (TNGX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Tango Therapeutics, Inc. (TNGX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 11, 2026·SEC
Aug 11, 2026·SEC
Aug 6, 2026·SEC
Get notified when TNGX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Tango Therapeutics, Inc. (TNGX) stock FAQ — growth, dividends, profitability & financials explained
Tango Therapeutics, Inc. (TNGX) reported $53.8M in revenue for fiscal year 2025. This represents a 118% increase from $24.6M in 2019.
Tango Therapeutics, Inc. (TNGX) grew revenue by 48.3% over the past year. This is strong growth.
Tango Therapeutics, Inc. (TNGX) reported a net loss of $123.7M for fiscal year 2025.
Tango Therapeutics, Inc. (TNGX) has a return on equity (ROE) of -37.2%. Negative ROE indicates the company is unprofitable.
Tango Therapeutics, Inc. (TNGX) had negative free cash flow of $144.3M in fiscal year 2025, likely due to heavy capital investments.
